Medizinische Universität Graz Austria/Österreich - Forschungsportal - Medical University of Graz

Logo MUG-Forschungsportal

Inhalte:

  • => Welche Forschungsthemen werden an der Medizinischen Universität bearbeitet?.
  • => Wer ist daran beteiligt und welche Methoden werden angewandt?.
  • => Welche Fördergeber unterstützen welche Projekte?.
  • => Wo werden Forschungsergebnisse publiziert?.

Facts and Figures: 2.590 Forscher*innenprofile (davon 1582 mit ORCID-ID), 8.715 Forschungsprojekte, 154.072 Publikationen, Posters und Vorträge, 64.010 Volltextlinks (davon Volltext frei zugänglich: > 28.094 (Open Access) )

Aktuelle Zitierungen im Web of Science: 1.969.110, davon 3.871 citation classics (>=100 Zitierungen) Summe Altmetrics Score: 297.168

Aktuell durch Fördergeber bewilligte Forschungsprojekte:

HER2-gerichteter M13-Bakteriophage als Träger für TRAIL zur gezielten Therapie von Brustkrebs
Projektleitung: Eigenfeld Marco
Laufzeit: 01.10.2025 - 30.09.2027
Geldgeber: Österreichische Agentur für internationale Mobilität und Kooperation in Bildung, Wissenschaft und Forschung, OeAD GmbH (ÖAD)

Auf dem Weg zu einem umfassenden Atlas des menschlichen Atmungsmikrobioms: Taxonomische, genomische und funktionelle Perspektiven
Projektleitung: Moissl-Eichinger Christine
Laufzeit: 01.08.2025 - 31.07.2026
Geldgeber: MEFOgraz

> Weitere neue Projekte

Die aktuellsten Publikationen in "Top-Journalen" (Top 20 % Impact Ranking):


08.08.2025:

Masi, S; Dalpiaz, H; Piludu, S; Piani, F; Fiorini, G; Borghi, C New strategies for the treatment of hyperkalemia.
Eur J Intern Med. 2025; 132:18-26 Doi: 10.1016/j.ejim.2024.10.016
PubMed FullText FullText_MUG

 

08.08.2025:

Saxena, M; Laffin, L; Borghi, C; Fernandez, Fernandez, B; Ghali, JK; Kopjar, B; Polu, K; Roger, SD; Slingsby, BT; Strutz, F; Vogt, L; Weir, MR; Rodman, D, , Launch-HTN, Investigators Lorundrostat in Participants With Uncontrolled Hypertension and Treatment-Resistant Hypertension: The Launch-HTN Randomized Clinical Trial.
JAMA. 2025; 334(5):409-418 Doi: 10.1001/jama.2025.9413 [OPEN ACCESS]
PubMed PUBMED Central FullText FullText_MUG

 

08.08.2025:

Klötzer, KA; Abedini, A; Li, S; Balzer, MS; Liang, X; Levinsohn, J; Ha, E; Dumoulin, B; Hogan, JJ; Quinn, G; Bloom, RD; Schuller, M; Eller, K; Halmos, B; Zhang, NR; Susztak, K Analysis of individual patient pathway coordination in a cross-species single-cell kidney atlas.
Nat Genet. 2025; Doi: 10.1038/s41588-025-02285-0
PubMed FullText FullText_MUG

 

04.08.2025:

Vladi, N; Englisch, C; Berger, JM; Moik, F; Berghoff, AS; Preusser, M; Pabinger, I; Ay, C Validation of risk assessment models for venous thromboembolism in patients with cancer receiving systemic therapies
BLOOD ADV. 2025; 9(13): 3340-3349. Doi: 10.1182/bloodadvances.2025016044 [OPEN ACCESS]
Web of Science PubMed PUBMED Central FullText FullText_MUG

 

04.08.2025:

Zurl, H; Korn, SM; Pohl, KK; Qian, Z; Piccolini, A; Iyer, HS; Leapman, MS; Ahyai, S; Shariat, SF; Trinh, QD; Thiel, CL; Loeb, S; Cole, AP Estimating the Carbon Emissions of a Single Prostate-specific Antigen Test: Results from a Cradle-to-grave Life Cycle Assessment.
Eur Urol Focus. 2025; Doi: 10.1016/j.euf.2025.07.006
PubMed FullText FullText_MUG

 

04.08.2025:

Spittle, AJ; Marschik, PB; Adde, L; Badawi, N; Byrne, R; Bos, AF; Chatelin, A; Coughlan, J; Fedeli, F; Guzzetta, A; Ho, ESL; Johnson, MJ; Kwong, A; McEwan, A; Morgan, C; Mughogho, A; Murray, DM; Orlandi, S; Peyton, C; Prosser, LA; Ritterband-Rosenbaum, A; Tran, T; Zhang, D; Passmore, E Towards universal early screening for cerebral palsy: a roadmap for automated General Movements Assessment.
EClinicalMedicine. 2025; 86:103379 Doi: 10.1016/j.eclinm.2025.103379 [OPEN ACCESS]
PubMed PUBMED Central FullText FullText_MUG

 

04.08.2025:

Fröhlich, E; Bordoni, A; Mohsenzada, N; Mitsche, S; Schröttner, H; Zellnitz-Neugebauer, S Development of Co-Amorphous Systems for Inhalation Therapy-Part 1: From Model Prediction to Clinical Success.
Pharmaceutics. 2025; 17(7): Doi: 10.3390/pharmaceutics17070922 [OPEN ACCESS]
PubMed PUBMED Central FullText FullText_MUG

 

04.08.2025:

Tang, G; Carr, AV; Perez, C; Ramos, Sarmiento, K; Levy, L; Lampe, JW; Diener, C; Gibbons, SM Metagenomic estimation of absolute bacterial biomass in the mammalian gut through host-derived read normalization.
mSystems. 2025; e0098425 Doi: 10.1128/msystems.00984-25
PubMed FullText FullText_MUG

 

04.08.2025:

Akyol, A; Çimen, Ş; Gottschalk, B; Erdoğan, YC; Lischnig, A; Barton, Alston, A; Digigow, R; Flühmann, B; Eroğlu, E; Graier, WF; Malli, R Tracking Intracellular Labile Iron with a Genetically Encoded Fluorescent Reporter System Based on Protein Stability.
ACS Sens. 2025; Doi: 10.1021/acssensors.5c01165
PubMed FullText FullText_MUG

 

04.08.2025:

Soowamber, ML; Bond, M; Touma, Z; Langford, C; Sanchez-Alvarez, C; Abril, A; Aydin, SZ; Buttgereit, F; Camellino, D; Cid, MC; Grayson, PC; Hellmich, B; Lichliter, W; Kermani, TA; Khalidi, NA; Mackie, SL; Matteson, EL; Maz, M; Merkel, PA; Monach, PA; Neill, L; Ponte, C; Salvarani, C; Schmidt, WA; Villiger, PM; Warrington, KJ; Whitlock, M; Ramiro, S; Dejaco, C A glossary of signs and symptoms of giant cell arteritis.
Ann Rheum Dis. 2025; Doi: 10.1016/j.ard.2025.06.2126
PubMed FullText FullText_MUG

 

04.08.2025:

Diaz-Gil, D; Gierlinger, G; Silva-Gomez, N; Rech, L; Ortiz-Urbina, J; Saraci, K; Koutsogiannaki, S; Wolf, CM; Kozlik-Feldmann, RG; Mair, R; Melero-Martin, JM; Emani, SM; García-Cardeña, G; Del, Nido, PJ; Friehs, I Preclinical Assessment of Atorvastatin for Treatment of Endocardial Fibroelastosis.
JACC Basic Transl Sci. 2025; 101282 Doi: 10.1016/j.jacbts.2025.03.014
PubMed FullText FullText_MUG

 

04.08.2025:

Sedej, S; Stockner, A; Schreiber, R; Diwan, A; Breinbauer, R; Abdellatif, M Specific targeting of adipose tissue metabolism is superior to caloric restriction in treating obesity-related HFpEF.
Cardiovasc Diabetol. 2025; 24(1):311 Doi: 10.1186/s12933-025-02879-2 [OPEN ACCESS]
PubMed PUBMED Central FullText FullText_MUG

 

> Weitere aktuelle Publikationen in Top-Journals

Distribution of Med Uni Graz affiliated publications by field-normalized Journal Impact Factor (JIFnorm)


Med Uni Graz publications1 were assigned quintiles according to the normalized2 Clarivate’s Journal Impact Factor of the journal at the time of publication.


Proportional Distribution: The color-coded columns show the distribution by JIFnorm-quintiles, while the left vertical axis indicates the proportion relative to the total articles published in a given year. The red line shows the total number of articles published each year (right vertical axis).


JIFnorm: Proportional Distribution


Example 1: Around 40% of the over 500 articles with Med Uni Graz affiliation published in 2019 had a normalized JIF > 0.8 (QU1).
Example 2: The proportion of articles published in journals with a normalized JIF < 0.4 (QU4 and QU5) has remained under 20% since 2010.

Absolute Impact: The sum of the normalized JIFs for all published articles in a given year, color-coded according to the respective quintile.


JIFnorm: Absolut Impact


1 This analysis considered only publications categorized as full papers/original articles.

2 IFnorm = (number of journals in WoS category - ranking of journal + 1) / number of journals in JCR SCIE/SSCI category. An IFnorm of 0.8 means that 20% of the journals in this subject category have a higher IF than the respective journal. The highest possible IFnorm is 1, which means that this journal currently has the highest IF in this subject category.

© Med Uni Graz Impressum